These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17599134)

  • 1. [Generic preparations are a nuisance].
    Lyftingsmo S
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1802-3. PubMed ID: 17599134
    [No Abstract]   [Full Text] [Related]  

  • 2. [Generic preparations and name confusion].
    Nielsen J
    Ugeskr Laeger; 2004 May; 166(23):2273. PubMed ID: 15487531
    [No Abstract]   [Full Text] [Related]  

  • 3. New inconvenient trend in advertising medicine.
    Salunke AZ
    J Indian Med Assoc; 1994 Nov; 92(11):381. PubMed ID: 7890949
    [No Abstract]   [Full Text] [Related]  

  • 4. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimizing look-alike generic mix-ups.
    Cohen MR; Davis NM
    Am Pharm; 1994 Mar; NS34(3):22-3. PubMed ID: 8192095
    [No Abstract]   [Full Text] [Related]  

  • 6. [Confusing drug information].
    Overø J
    Ugeskr Laeger; 2003 Nov; 165(48):4668; author reply 4668-9. PubMed ID: 14677474
    [No Abstract]   [Full Text] [Related]  

  • 7. [Wrong solution of a serious problem].
    Verland K
    Ugeskr Laeger; 2004 May; 166(20):1920. PubMed ID: 15202388
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug promotion.
    Hoberman D
    N Engl J Med; 1995 Apr; 332(15):1031; author reply 1033. PubMed ID: 7885412
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drugs and the public--an example of asymmetrical information].
    Hanson J
    Lakartidningen; 2001 Dec; 98(51-52):5922. PubMed ID: 11806273
    [No Abstract]   [Full Text] [Related]  

  • 10. Advertising and generic market entry.
    Königbauer I
    J Health Econ; 2007 Mar; 26(2):286-305. PubMed ID: 17011648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omissions in advertising.
    Simpson FO
    N Z Med J; 1973 Jun; 77(493):412 passim. PubMed ID: 4516044
    [No Abstract]   [Full Text] [Related]  

  • 12. [Should we accept defective copies?].
    Ostholm I
    Lakartidningen; 1993 Oct; 90(43):3747-8. PubMed ID: 8231521
    [No Abstract]   [Full Text] [Related]  

  • 13. [More than 1 out of 100 will have myocardial infarction and stroke because of enalapril--effect of drug package inserts?].
    Sandström H
    Lakartidningen; 2006 Feb 22-28; 103(8):564, 567; discussion 567. PubMed ID: 16570783
    [No Abstract]   [Full Text] [Related]  

  • 14. [Swedish confusion about generic preparations].
    Furuskog P
    Lakartidningen; 2006 Mar 1-7; 103(9):668. PubMed ID: 16583550
    [No Abstract]   [Full Text] [Related]  

  • 15. [Information from drug producers].
    Oye I
    Tidsskr Nor Laegeforen; 1977 May; 97(13):654-6. PubMed ID: 867358
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 17. The 'little, round, white pill' problem.
    Benfield WR
    Am Pharm; 1992 Jun; NS32(6):44-7. PubMed ID: 1615839
    [No Abstract]   [Full Text] [Related]  

  • 18. [Misuse of literature references in advertising].
    Jørgen E
    Ugeskr Laeger; 2004 Nov; 166(48):4393; author reply 4393-4. PubMed ID: 15587640
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug industry's "offers" to health personnel].
    Møller N
    Ugeskr Laeger; 2007 Nov; 169(47):4081. PubMed ID: 18087788
    [No Abstract]   [Full Text] [Related]  

  • 20. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.